03:00 , Aug 10, 2018 |  BC Innovations  |  Targets & Mechanisms

Getting to function

A new target for sarcopenia that increases muscle function directly, in addition to adding muscle mass, could help address calls from patients and regulators to make functional recovery central to drug development in the indication. Sarcopenia...
20:06 , Aug 1, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Lung cancer Patient sample, cell culture and mouse studies suggest inhibiting activin signaling could enhance the efficacy of platinum-based chemotherapy in KRAS-mutant lung cancer. In 59 patients with stage IV non-small cell lung cancer (NSCLC)...
04:15 , Apr 13, 2018 |  BC Innovations  |  Targets & Mechanisms

Hello RNA

BioCentury’s analysis of new and emerging targets presented at this year’s AACR meeting reveals a surge in activity in non-coding RNAs, as researchers continue to expand target space. The results also reflect the ongoing high...
22:08 , Apr 4, 2017 |  BC Innovations  |  Distillery Therapeutics

Inflammation

INDICATION: Asthma Patient sample, cell culture and mouse studies suggest stimulating T cells with activin A could help treat allergic asthma. In primary CD4+ T cells isolated from asthma patients and stimulated with mixed-grass extract-loaded monocytes,...
20:41 , Nov 9, 2016 |  BC Innovations  |  Distillery Therapeutics

Musculoskeletal

INDICATION: Osteoporosis Mouse studies suggest inhibiting GDF11 could help treat osteoporosis. In a mouse model of estrogen deficiency-induced bone loss, an anti-GDF11 mAb increased the number, thickness and volume of trabeculae in the distal femur metaphysis,...
07:00 , May 30, 2016 |  BC Week In Review  |  Clinical News

STM 434: Preliminary Phase I data

Preliminary data from 22 patients with advanced solid tumors in a 3-part, open-label, dose-escalation, U.S. Phase I trial showed that 0.25, 0.5, 0.75 and 1 mg/kg doses of IV STM 434 every 2-4 weeks led...
07:00 , Mar 31, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Not applicable

Endocrine/metabolic disease INDICATION: Infertility Cell culture and mouse studies suggest spermatid-like cells derived from embryonic stem cells (ESCs) could help treat infertility. Haploid spermatid-like cells were generated by reprogramming a mouse ESC line with activin A, fibroblast...
08:00 , Dec 17, 2015 |  BC Innovations  |  Tools & Techniques

Heartfelt conversion

A group of Chinese and American researchers have developed the first virus-free cellular reprogramming method that can turn skin cells into cardiac progenitors at an efficiency high enough for clinical use. The U.S. arm is...
08:00 , Dec 15, 2015 |  BC Extra  |  Clinical News

Atara looks to pipeline after Phase II failure

Atara Biotherapeutics Inc. (NASDAQ:ATRA) plans to focus its efforts on a pipeline of four clinical oncology and immunotherapy candidates after PINTA 745 missed the primary endpoint of a Phase II trial to treat protein energy...
08:00 , Dec 3, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Heart and neural crest derivatives expressed 2 (HAND2); myocyte enhancer factor 2C (Mef2c); bone morphogenetic protein 4 (BMP4)

Cardiovascular disease INDICATION: Myocardial infarction (MI) Studies in cells and mice suggest a protein-based method for reprogramming human dermal fibroblasts into cardiac progenitor cells could help regenerate heart tissue after MI. In vitro, incubation of human dermal...